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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of non-small-cell lung cancer (NSCLC)
Incidence
. The crude incidence of lung cancer in the European Union
is 52.5/100 000 per year, the mortality 48.7/100 000 per
year. Among men the rates are 82.5 and 77.0/100 000 per
year, among women 23.9 and 22.3/100 000 per year,
respectively. NSCLC accounts for 80% of all cases. About
90% of lung cancer mortality among men (and 80% among
women) is attributable to smoking.
Diagnosis
. Pathological diagnosis should be made according to the
WHO classification from a bronchoscopic, tru-cut or surgi-
cal biopsy or fine needle aspiration.
Staging and risk assessment
. Complete history and physical examination, chest X-ray and
CT scan of the chest and upper abdomen if local therapy is
being considered. Neurologic history and examination (with
a CT scan and/or MRI of the brain if results are abnormal).
. Mediastinal lymph node biopsy for operable NSCLC if CT
scan shows nodes >1 cm in shortest transverse axis.
. PET scan if warranted in resectable patients.
. Bone scintigraphy, in the presence of bone pain, elevated
serum calcium level, or elevated alkaline phosphatase level.
. Biopsy (or MRI or PET scan) to rule out metastatic disease
in otherwise potentially resectable patients with an isolated
adrenal mass or liver lesion.
. Patients with NSCLC shall be staged according to the
TNM-2002 system and be grouped into the risk categories
shown in Table 1.
Treatment of stage I–II disease
. Surgery remains the standard treatment of early stage
NSCLC. Adjuvant chemotherapy should be considered [II,
A]. Postoperative radiotherapy is not recommended [I, A].
. Curative radiotherapy as a single modality can achieve a
5-year survival rate of up to 40% in selected patients with
clinical stage I disease, and should be considered in cases of
medically inoperable stage I and II disease.
Treatment of stage III disease
. Preoperative chemotherapy is standard for resectable stage
IIIA. In randomized trials the survival of stage IIIA patients
was significantly better with induction chemotherapy plus
surgical resection than with resection alone [I, A].
. Platinum-based chemotherapy and thoracic radiotherapy is
the standard treatment for locally advanced, unresectable
Stage IIIB NSCLC or medically inoperable stage IIIA
NSCLC [I, A].
Treatment of stage IV disease
. Platinum-based chemotherapy combined with vinorelbine,
gemcitabine or taxanes prolongs survival, improves quality
of life, and controls symptoms in patients with good
performance status [I, A].
Second-line chemotherapy
. Second-line chemotherapy (docetaxel, pemetrexate)
improves disease-related symptoms and improves survival
in selected patients [II, B].
Response evaluation
. Response evaluation is mandatory after 2 or 3 cycles of
chemotherapy by repetition of the initial radiographic tests.
Follow-up
. The optimal approach to post-treatment management of
patients with thoracic malignancies, including the role of
radiologic evaluation, is controversial. For patients treated
with curative intent, a history and physical examination
should be performed every 3 months during the first 2
years, and every 6 months thereafter.
Table 1.
Occult carcinoma Tx N0 M0
Stage 0 Tis N0 M0
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T1 N1 M0
Stage IIB T2 N1 M0
T3 N0 M0
Stage IIIA T1, T2 N2 M0
T3 N1, N2 M0
Stage IIIB Any T N3 M0
T4 Any N M0
Stage IV Any T Any N M1
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Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the expert
authors and the ESMO faculty.
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